The content on this site is intended for healthcare professionals only
Dr Chetan Dhamne speaks to ecancer about a randomised, double-blind trial evaluating acyclovir pre-exposure prophylaxis for varicella-seronegative children receiving intensive chemotherapy for haematolymphoid malignancies.
He reports that acyclovir reduced the incidence of varicella from 21.2% with placebo to 1.8%, representing a 90% relative reduction in infection.
Dr Dhamne explains that the trial was stopped early for efficacy after meeting its predefined statistical boundary, with no drug-related toxicity observed.
He highlights that oral acyclovir could provide a simple, safe and relatively inexpensive strategy for preventing varicella-related morbidity and treatment interruptions, particularly in resource-constrained paediatric oncology settings where exposure is difficult to control.
Daratumumab and isatuximab show comparable efficacy in newly diagnosed multiple myeloma
Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival
Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL
Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM
Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM
Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM
Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL
